Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.43
JAZZ's Cash to Debt is ranked higher than
53% of the 1275 Companies
in the Global Biotechnology industry.

( Industry Median: 69.96 vs. JAZZ: 0.43 )
JAZZ' s 10-Year Cash to Debt Range
Min: 0.1   Max: No Debt
Current: 0.43

Equity to Asset 0.40
JAZZ's Equity to Asset is ranked higher than
59% of the 970 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. JAZZ: 0.40 )
JAZZ' s 10-Year Equity to Asset Range
Min: -0.84   Max: 0.87
Current: 0.4

-0.84
0.87
F-Score: 5
Z-Score: 3.73
M-Score: -2.46
WACC vs ROIC
8.37%
3.34%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 14.82
JAZZ's Operating margin (%) is ranked higher than
91% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -71.67 vs. JAZZ: 14.82 )
JAZZ' s 10-Year Operating margin (%) Range
Min: -365.84   Max: 46.95
Current: 14.82

-365.84
46.95
Net-margin (%) 2.97
JAZZ's Net-margin (%) is ranked higher than
86% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. JAZZ: 2.97 )
JAZZ' s 10-Year Net-margin (%) Range
Min: -397.15   Max: 49.25
Current: 2.97

-397.15
49.25
ROE (%) 2.50
JAZZ's ROE (%) is ranked higher than
88% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. JAZZ: 2.50 )
JAZZ' s 10-Year ROE (%) Range
Min: 17.9   Max: 111.92
Current: 2.5

17.9
111.92
ROA (%) 1.14
JAZZ's ROA (%) is ranked higher than
88% of the 1279 Companies
in the Global Biotechnology industry.

( Industry Median: -27.24 vs. JAZZ: 1.14 )
JAZZ' s 10-Year ROA (%) Range
Min: -113.42   Max: 64.21
Current: 1.14

-113.42
64.21
ROC (Joel Greenblatt) (%) 200.94
JAZZ's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 1249 Companies
in the Global Biotechnology industry.

( Industry Median: -347.70 vs. JAZZ: 200.94 )
JAZZ' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -8082.84   Max: 11377.93
Current: 200.94

-8082.84
11377.93
Revenue Growth (3Y)(%) 47.60
JAZZ's Revenue Growth (3Y)(%) is ranked higher than
96% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: -0.50 vs. JAZZ: 47.60 )
JAZZ' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 47.6
Current: 47.6

0
47.6
EBITDA Growth (3Y)(%) 59.50
JAZZ's EBITDA Growth (3Y)(%) is ranked higher than
91% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. JAZZ: 59.50 )
JAZZ' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 75.9
Current: 59.5

0
75.9
EPS Growth (3Y)(%) 61.70
JAZZ's EPS Growth (3Y)(%) is ranked higher than
63% of the 708 Companies
in the Global Biotechnology industry.

( Industry Median: -8.20 vs. JAZZ: 61.70 )
JAZZ' s 10-Year EPS Growth (3Y)(%) Range
Min: -66.4   Max: 76.1
Current: 61.7

-66.4
76.1
» JAZZ's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

JAZZ Guru Trades in Q1 2014

George Soros 3,600 sh (New)
Jim Simons 54,793 sh (New)
Steve Mandel 2,344,486 sh (New)
Joel Greenblatt 7,367 sh (New)
Paul Tudor Jones 4,100 sh (+39.6%)
NWQ Managers 173,919 sh (+26.81%)
Pioneer Investments 268,669 sh (+11.1%)
RS Investment Management 245,052 sh (-39.25%)
Steven Cohen 2,533 sh (-72.4%)
Chuck Royce 31,900 sh (-77.31%)
» More
Q2 2014

JAZZ Guru Trades in Q2 2014

RS Investment Management 323,097 sh (+31.85%)
NWQ Managers 206,924 sh (+18.98%)
Pioneer Investments 311,592 sh (+15.98%)
George Soros Sold Out
Chuck Royce Sold Out
Joel Greenblatt Sold Out
Steve Mandel 2,087,127 sh (-10.98%)
Paul Tudor Jones 1,400 sh (-65.85%)
Jim Simons 11,200 sh (-79.56%)
» More
Q3 2014

JAZZ Guru Trades in Q3 2014

Paul Tudor Jones 1,600 sh (+14.29%)
Pioneer Investments 311,004 sh (unchged)
Jim Simons Sold Out
RS Investment Management 289,982 sh (-10.25%)
Steve Mandel 1,788,607 sh (-14.3%)
NWQ Managers 138,705 sh (-32.97%)
» More
Q4 2014

JAZZ Guru Trades in Q4 2014

Steve Mandel 1,883,654 sh (+5.31%)
RS Investment Management 287,828 sh (-0.74%)
Paul Tudor Jones 1,400 sh (-12.5%)
Pioneer Investments 253,843 sh (-18.38%)
NWQ Managers 64,783 sh (-53.29%)
» More
» Details

Insider Trades

Latest Guru Trades with JAZZ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
NWQ Managers 2014-12-31 Reduce -53.29%0.13%$142.72 - $183.03 $ 170.092%64783
Steve Mandel 2014-09-30 Reduce -14.3%0.17%$132.55 - $174.37 $ 170.0911%1788607
NWQ Managers 2014-09-30 Reduce -32.97%0.1%$132.55 - $174.37 $ 170.0911%138705
Steve Mandel 2014-06-30 Reduce -10.98%0.15%$124.63 - $154.82 $ 170.0923%2087127
Joel Greenblatt 2014-06-30 Sold Out 0.02%$124.63 - $154.82 $ 170.0923%0
George Soros 2014-06-30 Sold Out $124.63 - $154.82 $ 170.0923%0
Steve Mandel 2014-03-31 New Buy1.4%$125.51 - $174.98 $ 170.0913%2344486
NWQ Managers 2014-03-31 Add 26.81%0.04%$125.51 - $174.98 $ 170.0913%173919
Joel Greenblatt 2014-03-31 New Buy0.02%$125.51 - $174.98 $ 170.0913%7367
George Soros 2014-03-31 New Buy$125.51 - $174.98 $ 170.0913%3600
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Jazz Pharmaceuticals PLC

Weekly Insider Sells Highlight: JAZZ, HD, ESRX, SCI
According to GuruFocus Insider Data, the largest insider sells over the past week were: Jazz Pharmaceuticals PLC, Home Depot Inc., Express Scripts and Service Corporation International Inc. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 409.50
JAZZ's P/E(ttm) is ranked higher than
88% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. JAZZ: 409.50 )
JAZZ' s 10-Year P/E(ttm) Range
Min: 10.72   Max: 418.69
Current: 409.5

10.72
418.69
Forward P/E 13.89
JAZZ's Forward P/E is ranked higher than
98% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. JAZZ: 13.89 )
N/A
PE(NRI) 395.60
JAZZ's PE(NRI) is ranked higher than
88% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. JAZZ: 395.60 )
JAZZ' s 10-Year PE(NRI) Range
Min: 11.86   Max: 414.79
Current: 395.6

11.86
414.79
P/B 7.90
JAZZ's P/B is ranked higher than
70% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. JAZZ: 7.90 )
JAZZ' s 10-Year P/B Range
Min: 2.46   Max: 32.21
Current: 7.9

2.46
32.21
P/S 9.90
JAZZ's P/S is ranked higher than
84% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 29.06 vs. JAZZ: 9.90 )
JAZZ' s 10-Year P/S Range
Min: 0.22   Max: 12.01
Current: 9.9

0.22
12.01
PFCF 89.90
JAZZ's PFCF is ranked higher than
93% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. JAZZ: 89.90 )
JAZZ' s 10-Year PFCF Range
Min: 11.82   Max: 91.94
Current: 89.9

11.82
91.94
POCF 30.16
JAZZ's POCF is ranked higher than
94% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. JAZZ: 30.16 )
JAZZ' s 10-Year POCF Range
Min: 9.6   Max: 54.63
Current: 30.16

9.6
54.63
EV-to-EBIT 69.20
JAZZ's EV-to-EBIT is ranked higher than
91% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. JAZZ: 69.20 )
JAZZ' s 10-Year EV-to-EBIT Range
Min: -8.5   Max: 74.6
Current: 69.2

-8.5
74.6
Shiller P/E 114.90
JAZZ's Shiller P/E is ranked higher than
95% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. JAZZ: 114.90 )
JAZZ' s 10-Year Shiller P/E Range
Min: 97.99   Max: 11692
Current: 114.9

97.99
11692
Current Ratio 3.93
JAZZ's Current Ratio is ranked higher than
74% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. JAZZ: 3.93 )
JAZZ' s 10-Year Current Ratio Range
Min: 0.2   Max: 5.1
Current: 3.93

0.2
5.1
Quick Ratio 3.76
JAZZ's Quick Ratio is ranked higher than
75% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. JAZZ: 3.76 )
JAZZ' s 10-Year Quick Ratio Range
Min: 0.17   Max: 4.99
Current: 3.76

0.17
4.99
Days Inventory 103.02
JAZZ's Days Inventory is ranked higher than
89% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. JAZZ: 103.02 )
JAZZ' s 10-Year Days Inventory Range
Min: 70.82   Max: 164.69
Current: 103.02

70.82
164.69
Days Sales Outstanding 63.37
JAZZ's Days Sales Outstanding is ranked higher than
83% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 114.29 vs. JAZZ: 63.37 )
JAZZ' s 10-Year Days Sales Outstanding Range
Min: 30.12   Max: 61.23
Current: 63.37

30.12
61.23

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 3.90
JAZZ's Price/DCF (Projected) is ranked higher than
94% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. JAZZ: 3.90 )
JAZZ' s 10-Year Price/DCF (Projected) Range
Min: 2.23   Max: 6.62
Current: 3.9

2.23
6.62
Price/Median PS Value 1.90
JAZZ's Price/Median PS Value is ranked higher than
77% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 2.46 vs. JAZZ: 1.90 )
JAZZ' s 10-Year Price/Median PS Value Range
Min: 0.06   Max: 1.74
Current: 1.9

0.06
1.74
Price/Peter Lynch Fair Value 16.20
JAZZ's Price/Peter Lynch Fair Value is ranked higher than
97% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. JAZZ: 16.20 )
JAZZ' s 10-Year Price/Peter Lynch Fair Value Range
Min: 1.04   Max: 14.94
Current: 16.2

1.04
14.94
Earnings Yield (Greenblatt) 1.30
JAZZ's Earnings Yield (Greenblatt) is ranked higher than
90% of the 1255 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. JAZZ: 1.30 )
JAZZ' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.3   Max: 10.7
Current: 1.3

1.3
10.7
Forward Rate of Return (Yacktman) 49.31
JAZZ's Forward Rate of Return (Yacktman) is ranked higher than
96% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 15.72 vs. JAZZ: 49.31 )
JAZZ' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -43.1   Max: 49.5
Current: 49.31

-43.1
49.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:J7Z.Germany,
Jazz Pharmaceuticals PLC was originally incorporated in California in March 2003 and was reincorporated in Delaware in January 2004. The Company was originally formed as a private limited liability company in March 2005 under the name Azur Pharma Limited, and was subsequently re-registered as a public limited company under the name Azur Pharma Public Limited Company in October 2011. On January 18, 2012, the business of Jazz Pharmaceuticals, Inc. and Azur Pharma were combined in the Azur Merger in connection with which Azur Pharma was re-named Jazz Pharmaceuticals plc. It is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing differentiated products that address unmet medical needs. Its products includes Xyrem, Erwinaze, Prialt. Its commercial activities in the United States are dedicated to its marketed products Xyrem, Erwinaze, Prialt, FazaClo HD, FazaClo LD and Versacloz, as well as providing support for sales of certain of its other products. They have approximately 180 trained, experienced sales professionals who detail its marketed products to physicians in specialties appropriate for each marketed product in the United States. In Europe, they promote Erwinase to hematology and oncology specialists. The Company's commercial activities include marketing and related services and commercial support services. The Company also employ third party vendors, such as advertising agencies, market research firms and suppliers of marketing and other sales support related services, to assist with its commercial activities. Some of these competitors include Endo Health Solutions Inc., Forest Laboratories, Inc., Shire Pharmaceuticals, Inc., Teva and Valeant. Other than the manufacturing plant in Italy where they produce some active pharmaceutical ingredients, including the defibrotide drug substance, discussed in more detail below, the company do not have its own manufacturing capability for its products or product candidates, or their active pharmaceutical ingredients, or the capability to package its products. The research, testing, manufacturing, labeling, packaging, adverse event reporting, storage, advertising, promotion, sale, distribution, recordkeeping, importing and exporting of pharmaceutical products are subject to extensive regulation by the FDA, the European Commission and other regulatory authorities, and regulations differ from country to country. In the United States, the FDA, under the Federal Food, Drug and Cosmetic Act, or FDCA, and its implementing regulations, regulates the review, approval, manufacturing and marketing of pharmaceutical products.
» More Articles for JAZZ

Headlines

Articles On GuruFocus.com
Pharmaceutical Giant Merck Buys Cubist Pharma Dec 09 2014 
Growth Momentum Should Continue For This Pharmaceutical Company Nov 15 2014 
Jazz Pharmaceuticals: Growth Trajectory Can Continue In Future Sep 03 2014 
Weekly CFO Sells Highlight: Google Inc, Jazz Pharmaceuticals PLC, Jack in the Box Inc. Jun 30 2014 
Weekly Insider Sells Highlight: JAZZ, HD, ESRX, SCI Mar 11 2014 
Weekly CFO Sells Highlight: Jazz Pharmaceuticals PLC, Carnival PLC, Juniper Networks Inc., Home Depo Mar 10 2014 
comment on JAZZ Mar 21 2013 
optimized portfolio Jul 26 2011 
Jazz Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 08 2011 
Jazz Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 05 2010 

More From Our Partners
Company News for February 26, 2015 - Corporate Summary Feb 26 2015 - ZACKS

More From Other Websites
4 Big-Volume Stocks to Trade for Breakouts: La Jolla Pharma and More Mar 02 2015
Splunk Shoots Up After Hours; Monster Beverage Also Up Feb 26 2015
Jazz Pharmaceuticals Tops Q4 Earnings And Tests Buy Point Feb 26 2015
Company News for February 26, 2015 - Corporate Summary Feb 26 2015
Heavy News Day For Several Biotech Stocks Feb 25 2015
8 Stories JP Morgan Is Watching Today Feb 25 2015
Jazz Pharmaceuticals (JAZZ) Earnings Report: Q4 2014 Conference Call Transcript Feb 25 2015
Jazz Pharmaceuticals Tops Q4 Earnings, Provides Guidance - Analyst Blog Feb 25 2015
Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2014 Financial Results Feb 24 2015
Jazz Pharmaceuticals Sinks On Outlook, Halt In Drug Trial Feb 24 2015
Jazz tops Street 4Q forecasts Feb 24 2015
Jazz tops Street 4Q forecasts Feb 24 2015
Jazz Pharma Tops, But Stock Falls On Guidance Feb 24 2015
Hewlett-Packard, Jazz Pharmaceuticals Fall After-Hours Feb 24 2015
Jazz Pharmaceuticals PLC Earnings Call scheduled for 4:30 pm ET today Feb 24 2015
Stocks Rise A Bit On Yellen Testimony, Home Depot Results Feb 24 2015
Q4 2014 Jazz Pharmaceuticals PLC Earnings Release - After Market Close Feb 24 2015
Jazz Pharmaceuticals Announces Participation in Two Investor Conferences in March Feb 23 2015
Avago, Jazz, MercadoLibre Build Bases Before Q4 Reports Feb 23 2015
Jazz Pharmaceuticals Announces Participation in Two Investor Conferences in March Feb 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK